Radha Sanka, MD
Ophthalmology · Mount Pleasant, WINPI 1508042060
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,435 of the $14,778 with a category attached, or 70.6%. It is spread thinly across 32 manufacturers, the largest accounting for just 19.7%. Among ophthalmology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 331 payments — averaging $44.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$3K
- Kala Pharmaceuticals, Inc.$2K
- Carl Zeiss Meditec USA, Inc.$1K
- Alcon$1K
- Glaukos Corporation$1K
- Rxsight Inc$903
- plus $6K from 26 others
Across 37 payments — averaging $3127.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$115K
- AbbVie$225
What the payments were for
- Consulting fees$1,3009%
- Speaking & faculty fees$5394%
- Travel & lodging$2,48517%
- Food & beverage$10,43571%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 44 | $2,913 |
| Kala Pharmaceuticals, Inc. | 15 | $1,626 |
| Carl Zeiss Meditec USA, Inc. | 16 | $1,166 |
| Alcon | 23 | $1,130 |
| Glaukos Corporation | 7 | $1,087 |
| Rxsight Inc | 12 | $903 |
| Bausch & Lomb Americas Inc. | 20 | $715 |
| AbbVie(2 entities) | 39 | $700 |
| NEW World Medical,inc. | 20 | $625 |
| Novartis | 37 | $602 |
| Sight Sciences, Inc. | 7 | $456 |
| Alcon Research LLC | 1 | $410 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $361 |
| Harrow Eye, LLC | 8 | $299 |
| Eyevance Pharmaceuticals LLC | 6 | $206 |
| Sun Pharmaceutical Industries Inc. | 4 | $196 |
| Dompe US, Inc. | 9 | $190 |
| Amgen(2 entities) | 10 | $174 |
| Oyster Point Pharma, Inc. | 11 | $171 |
| Carl Zeiss Meditec, Inc. | 2 | $123 |
| The Cameron-ehlen Group, Inc. | 3 | $122 |
| Ocular Therapeutix, Inc. | 7 | $121 |
| Shire North American Group Inc | 2 | $91 |
| Regeneron Healthcare Solutions, Inc. | 4 | $72 |
| Aerie Pharmaceuticals, Inc. | 4 | $70 |
| Astellas Pharma US Inc | 2 | $66 |
| Tarsus Pharmaceuticals, Inc. | 2 | $42 |
| Thea Pharma Inc. | 2 | $40 |
| Apellis Pharmaceuticals, Inc. | 2 | $36 |
| Beaver-visitec International, Inc. | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYSUVIS$1,436
- iStent Infinite$643
- Travoprost Intraocular Implant - iDose$500
- RXSIGHT CONTACT LENS$435
- RXSIGHT INJECTOR HANDPIECE$435
- RXSIGHT INJECTOR CARTRIDGE$435
- LIGHT ADJUSTABLE LENS (LAL)$435
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$435
- iDoseTR$258
- Kahook Dual Blade$240
- Clearpath$240
- Ahmed Glaucoma Valve$240
- Streamline$240
- OMNI(R) SURGICAL SYSTEM (US)$204
- SION SURGICAL INSTRUMENT$204
- iStent inject Trabecular Micro-Bypass Stent System$168
- INVELTYS$136
- IOLMaster 700$131
- MEL 90$131
- VisuMax$131
How this compares
$14,778 in reported general payments places this provider in the 95th percentile of 337 ophthalmology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 184 | $244,487 |
| RestasisCyclosporine | 103 | $102,675 |
| IlevroNepafenac | 222 | $85,282 |
| TyrvayaVarenicline Tartrate | 60 | $48,779 |
| CombiganBrimonidine Tartrate/Timolol | 62 | $23,670 |
| XdemvyLotilaner | 11 | $22,052 |
| ProlensaBromfenac Sodium | 54 | $20,115 |
| EysuvisLoteprednol Etabonate | 32 | $15,809 |
| RocklatanNetarsudil Mesylat/Latanoprost | 28 | $13,433 |
| MoxifloxacinMoxifloxacin Hcl | 391 | $12,043 |
| VyzultaLatanoprostene Bunod | 23 | $10,732 |
| LumiganBimatoprost | 19 | $9,305 |
| Lotemax SmLoteprednol Etabonate | 31 | $8,849 |
| Prednisolone Acetate | 145 | $6,941 |
| Cyclosporine | 13 | $6,461 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $715 | $255,218207 claims |
| AbbVieRestasis, Combigan, Lumigan | $700 | $135,650184 claims |
| NovartisIlevro | $602 | $85,282222 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $171 | $48,77960 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm | $361 | $28,96585 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $42 | $22,05211 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $1,626 | $15,80932 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $70 | $13,43328 claims |
| AlconSimbrinza | $1,130 | $3,04215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 337 ophthalmology providers in Wisconsin.
Other ophthalmology in Mount Pleasant
- Inder SinghRacine$2.5M
- Deepak SambharaWausau$388K
- John VukichWauwatosa$356K
- Eugene EldridgeKenosha$294K
- Michael ShapiroMadison$71K
- Douglas SalmAppleton$38K
- Julia AgapovMadison$26K
- Thomas HarveyChippewa Falls$23K
- Michael VrabecAppleton$20K
- Philip SmithMinocqua$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.